98%
921
2 minutes
20
Interventional cardiology has recently advanced with innovations such as percutaneous transluminal coronary angioplasty (PTCA), transcatheter aortic valve replacement (TAVR), and the emergence of artificial intelligence (AI) as a transformative tool. This systematic review explored the current landscape, methodologies, and applications of AI in interventional cardiology. A comprehensive literature search was conducted following preferred reporting guidelines, identifying 20 studies after data extraction and quality assessment. AI-particularly machine learning (ML) and deep learning (DL)-enhances diagnostic accuracy and procedural efficiency. ML aids in arrhythmia detection and coronary plaque characterization, while DL supports imaging interpretation, robotic navigation, and catheter tracking. Clinical applications show AI's potential in predicting myocardial infarction, guiding personalized treatment, and improving resource management. Despite these benefits, challenges such as data privacy, algorithm transparency, and generalizability remain. Addressing these requires collaborative efforts and robust data sharing. Future priorities include integrating AI into routine clinical workflows, resolving regulatory barriers, and ensuring interpretability. Multidisciplinary collaboration is essential to address ethical considerations and uphold patient safety. The integration of AI in interventional cardiology offers significant potential to enhance patient care, procedural precision, and resource utilization. However, its adoption must be guided by careful attention to ethical, technical, and regulatory constraints. Overcoming these barriers through coordinated efforts may allow AI to redefine standards in cardiovascular care and enable a more precise, efficient, and patient-centered approach to interventional cardiology.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329261 | PMC |
http://dx.doi.org/10.7759/cureus.87494 | DOI Listing |
Herz
September 2025
Department of Cardiology, Heart Center Leipzig, University of Leipzig, Strümpellstraße 39, 04289, Leipzig, Deutschland.
Since the earliest studies on transcatheter aortic valve implantation (TAVI), the heart team concept has been an integral component of treatment planning for patients with aortic valve stenosis (AS). The primary objective is to ensure patient-specific, guideline-based treatment through the structured involvement of all relevant medical disciplines. The TAVI heart team is strongly recommended with a class I indication in both European and US clinical guidelines.
View Article and Find Full Text PDFClin Res Cardiol
September 2025
Department of (Interventional) Cardiology, Thoraxcenter, Erasmus University Medical Center, Room Rg-628, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands.
Background: Fractional flow reserve (FFR) for non-culprit lesions (NCLs) in patients with ST-elevation myocardial infarction (STEMI) can be influenced by temporary changes in microvascular resistance. Angiography-derived vessel fractional flow reserve (vFFR) has been tested as a less-invasive alternative.
Aims: The FAST STEMI II study aimed to assess the diagnostic performance of acute-setting vFFR vs.
JACC Cardiovasc Imaging
September 2025
Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; UPMC Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. Electronic address:
Background: Residual leaks are common after left atrial appendage occlusion (LAAO).
Objectives: The authors aimed to systematically evaluate the prognostic implications of residual left atrial appendage (LAA) patency and peridevice leaks (PDLs) detected by cardiac computed tomography (CT) following LAAO.
Methods: The authors used traditional meta-analytical methods and a Bayesian framework to assess the probability of increased risks associated with these residual leaks.
JTCVS Open
August 2025
Division of Cardiothoracic Surgery, Children's Hospital of Philadelphia, Philadelphia, Pa.
[This corrects the article DOI: 10.1016/j.xjon.
View Article and Find Full Text PDFCureus
August 2025
Internal Medicine, University of Health Sciences, Lahore, PAK.
Heart failure remains a leading global health burden affecting over 64 million individuals worldwide, with limited effective acute management strategies. Carperitide, a recombinant form of human atrial natriuretic peptide, has been primarily used in Japan for acute heart failure treatment, but its clinical efficacy remains controversial. This systematic review and meta-analysis aimed to evaluate the clinical outcomes of carperitide in heart failure patients.
View Article and Find Full Text PDF